GGA
TEVA icon

Granite Group Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Granite Group Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$254K Hold
7,489
– – 0.15% 74
2026
Q1 		$220K Buy
+7,489
New +$241K 0.13% 81

Other funds holding TEVA

HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
AIIMS
Analyst IMS Investment Management Services Tel-Aviv, Israel $4.3B AUM 37.33% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
PMG
Private Management Group Irvine, California $3.8B AUM 23.19% 1-Year Est. Return
FAF
Fjarde Ap-fonden Stockholm, Sweden $20.9B AUM 36.93% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Granite Group Advisors's TEVA Position: Q2 2026 in Review

Granite Group Advisors held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 7,489 shares worth $254K. The position accounts for 0.15% of the portfolio, ranked #74.

Granite Group Advisors first reported a position in TEVA in Q1 2026 and has held it in 2 quarters since. 232 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Granite Group Advisors held 7,489 shares of Teva Pharmaceuticals worth $254K as of Q2 2026.
  • Granite Group Advisors left its Teva Pharmaceuticals share count unchanged in Q2 2026.
  • Teva Pharmaceuticals made up 0.15% of Granite Group Advisors's portfolio in Q2 2026, its #74 holding.
  • Granite Group Advisors first reported a position in Teva Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 232 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Granite Group Advisors's 13F filing for Q2 2026, filed 23 Jul 2026.